LMAT vs. MDXG, CSII, CRY, SIBN, OFIX, STVN, INSP, MMSI, HAE, and AXNX
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include MiMedx Group (MDXG), Cardiovascular Systems (CSII), CryoLife (CRY), SI-BONE (SIBN), Orthofix Medical (OFIX), Stevanato Group (STVN), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Haemonetics (HAE), and Axonics (AXNX). These companies are all part of the "medical" sector.
MiMedx Group (NASDAQ:MDXG) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.
MiMedx Group currently has a consensus price target of $12.25, indicating a potential upside of 72.05%. LeMaitre Vascular has a consensus price target of $73.83, indicating a potential downside of 6.27%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than LeMaitre Vascular.
MiMedx Group has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
MiMedx Group has higher revenue and earnings than LeMaitre Vascular. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
LeMaitre Vascular received 467 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.27% of users gave MiMedx Group an outperform vote while only 70.86% of users gave LeMaitre Vascular an outperform vote.
MiMedx Group has a net margin of 18.63% compared to MiMedx Group's net margin of 16.99%. LeMaitre Vascular's return on equity of 39.42% beat MiMedx Group's return on equity.
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 1.3% of MiMedx Group shares are held by insiders. Comparatively, 10.8% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, MiMedx Group and MiMedx Group both had 3 articles in the media. MiMedx Group's average media sentiment score of 1.61 beat LeMaitre Vascular's score of 1.26 indicating that LeMaitre Vascular is being referred to more favorably in the news media.
Summary
MiMedx Group beats LeMaitre Vascular on 9 of the 17 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
